Additional Targets. (a) Within ninety (90) days prior to the commencement of the second 12-month period of the Research Program, ImClone may add up to *** relating to ImClone's Areas of Interest to the Collaboration by notifying CombiChem in writing that it wishes to designate such Target(s) as Additional Target(s); it being understood that the Project Team shall be obligated to simultaneously work on no more than *** Collaboration Targets as directed by the RMC.
Additional Targets. At any time during the Research Term, the parties may wish to expand the scope of the Research Program to cover targets in addition to the Targets. The parties shall determine in good faith negotiations whether they can agree on the terms of a separate agreement which shall cover the discovery, development and commercialization of compounds acting on those additional targets; provided, however, neither party shall be obligated to enter into such negotiations or to reach agreement if negotiations are conducted.
Additional Targets. In the event that the Selected Target Threshold has been reached, Novartis may from time to time during the Selection Term either:
Additional Targets. Commencing upon a Potential Target becoming an Additional Target in accordance with Section 2.2(a) (Grant of Option), Selecta hereby grants to Spark an exclusive (even as to Selecta and its Affiliates) right and license in the Field in the Territory, with the right to grant sublicenses, under the Selecta IP (i) to use, offer for sale, sell, import and otherwise Develop and Commercialize Licensed Products directed to such Additional Target, (ii) to make, have made and otherwise Manufacture Licensed Products directed to such Additional Target excluding the making, having made or Manufacturing of any Licensed Particles within such Licensed Products and (iii) contingent upon exercise of the Technology Transfer Option, make, have made and otherwise Manufacture Licensed Particles solely for inclusion in Licensed Products directed to such Additional Target and solely in accordance with Section 5.3 (Manufacturing Transfer).
Additional Targets. Pfizer shall have the right to add up to two (2) additional Targets (in addition to the Second Target and any Replacement Target designated pursuant to Sections 2.1.3 and 2.1.5, respectively), exercisable upon written notice to CytomX, at any time prior to the three year anniversary (“Target Expansion Window”) of the Effective Date, subject to availability of such Target and payment of the Additional Target Fee, if applicable, as specified in Section 2.1.8.
Additional Targets. At any time during the Screening Period, Cubist may provide Pharmacopeia notice that Cubist wishes to drop a Target from this Agreement and designate an additional target as a Target for all purposes of this Agreement. Within fifteen (15) days of receipt of such notice, Pharmacopeia shall, at its sole discretion, accept or deny the designation of each such proposed target as a Target by notice to Cubist. Upon Pharmacopeia's notice of such acceptance, if any, Cubist's right to negotiate a further agreement with respect to such dropped Target shall terminate.
Additional Targets. Pfizer shall have the right to add up to two (2) additional Targets (in addition to the Second Target and any Replacement Target designated pursuant to Sections 2.1.3 and 2.1.5, respectively), exercisable upon ***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. written notice to CytomX, at any time prior to the [***] (“Target Expansion Window”) of the Effective Date, subject to availability of such Target and payment of the Additional Target Fee, if applicable, as specified in Section 2.1.8.
Additional Targets. In connection with MAGENTA exercising its Exclusive Research Option Right for Targets other than the Initial Targets, MAGENTA shall follow the notification and selection procedures set forth in Section 3.3.3 with respect to such Targets (such Targets, once MAGENTA has exercised its Exclusive Research Option Right with respect thereto, together with the Initial Targets, the “Exclusive Research Targets”). In connection with MAGENTA’s exercise of its Exclusive Research Option Right for such other Targets, MAGENTA will pay HDPR the Research Target Fees as more fully set forth in Section 9.1.2.
Additional Targets. The Parties agree and acknowledge that as of the First Amendment Effective Date, Xxxx may name up to [**] Additional Targets (the “Remaining Additional Targets”). Notwithstanding Section 2.4(b) of the Agreement, and as consideration for the extension of the Research Program Term and waiver of the extension fees set forth in Section 6.3 of the Agreement, Xxxx agrees that during the applicable Calendar Years, it may only name up to the following number of Additional Targets (the “Annual Target Number”): (a) during the 2024 Calendar Year, [**] Additional Targets, and (b) during the 2025 Calendar Year, [**] Additional Targets. In the event Juno nominates fewer than the Annual Target Number for the applicable Calendar Year (the “Annual Target Deadline”), then Xxxx shall waive the ability to nominate the remaining number of Additional Target(s) for such Calendar Year, provided that Juno may exercise a one-time right to extend the Annual Target Deadline in a single Calendar Year for an additional twelve (12) months upon payment of a fee of [**]. For the avoidance of doubt, (a) such fee shall be payable, if at all, one time, and such payment shall apply with respect to up to the Annual Target Number of Additional Targets for the extended Calendar Year and (b) if such fee is paid with respect to Calendar Year 2025, then the Research Program Term shall expire on November 11, 2027.
Additional Targets. (a) The Parties agree that [*] Additional Targets shall be selected for screening under the Research Collaboration. The process for selection of such Additional Targets will be as follows:
